Understanding the psychological underpinnings of sexual motivation can be helpful in improving the sexual and relationship well-being of couples affected by vulvodynia, according to recent research.
According to a literature review, apart from the essential role that sex hormones play in modulating hypoactive sexual desire disorder (HSDD) through therapeutic interventions, a comprehensive understanding of the biologic mechanisms underlying the disorder is imperative.
Premenopausal and postmenopausal women treated with the combined agonist/antagonist flibanserin for hypoactive sexual desire disorder (HSDD) are likely to lose weight, according to a post hoc analysis of five studies.
Midpelvic attempted operative vaginal delivery (aOVD) does not increase risk of sexual dysfunction in women or their male partners nor are the women more likely to manifest symptoms of maternal postpartum depression at 6 months compared to counterparts who had low pelvic aOVD, according to a prospective study.
Women with arousal-specific sexual dysfunction are significantly less likely to perceive when their genitals are sexually aroused compared to women who have decreased sexual function or are sexually functional, according to an analysis of data from 5 studies
More than half of young adults between ages 18 and 39 with a cancer diagnosis reported problems with sexual function, according to a 2-year longitudinal study.
An integral part of a treatment plan for managing sexual dysfunction in women is the use of hormonal and pharmaceutical agents, a variety of which are available.
A stepwise approach ensures that all the potential issues and needs affecting a women’s sexual dysfunction are addressed prior to initiating management strategies.
Learn about the prevalence of HSDD and hear from Key Opinion Leaders about its effect on premenopausal women.
For particular groups of women, reluctance to talk about sexual difficulties may be enhanced by perceived societal judgements and misconceptions.